- Conditions
- Traditional Face to Face Training, Family Therapy Training and Implementation Platform (FTTIP)
- Interventions
- Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP), Training on CIFFTA competencies using Training and Coaching as Usual (TCAU)., Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)., Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP), Agency Engagement and Orientation as Usual
- Other
- Lead sponsor
- Training and Implementation Associates
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 475
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Tobacco Use Disorder
- Interventions
- nicotine transdermal system, bupropion, Medication Management, Mayo Counseling, placebo patch, placebo bupropion
- Drug · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
- Conditions
- Exercise
- Interventions
- Active Play planned movement program
- Behavioral
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Pancreatic Cancer
- Interventions
- Erlotinib, gemcitabine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Sacramento, California
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 4
- States / cities
- Duarte, California • Miami, Florida • Atlanta, Georgia + 1 more
- Conditions
- Obesity
- Interventions
- BWLI-College, Control
- Behavioral
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
- Interventions
- Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+
- Behavioral
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- Sweet Spot: Flexible high incentive condition, Sweet Spot: Flexible low incentive condition, Sweet Spot: Rigid high incentive condition, Sweet Spot: Rigid low incentive condition, FOTW: High incentive control condition, FOTW: Low incentive control condition, FOTW: High incentive treatment condition, FOTW: Low incentive treatment condition, Think Twice: Control condition, Think Twice: Treatment condition, WDR: Control condition, WDR: Treatment condition
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Esophageal Neoplasms, Esophageal Diseases
- Interventions
- Erlotinib, Avastin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- MOVES
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Ovarian Cancer
- Interventions
- Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
- Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Colonic Neoplasms
- Interventions
- Aerobic exercise, Progressive stretching
- Behavioral
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Oakland, California • Orlando, Florida • Boston, Massachusetts
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Interventions
- Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg, Olaparib Pill 200 mg, Olaparib Pill 250 mg, Olaparib Pill 300 mg, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
- Conditions
- Patellofemoral Pain Syndrome
- Interventions
- transcranial direct current stimulator
- Device
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Neurological Disorder
- Interventions
- Physical Activity Monitoring Device, Lifestyle Redesign Coaching
- Device · Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Myeloma
- Interventions
- recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Idelalisib, Ofatumumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 7
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Interventions
- AZD6244, MK-2206, Lapatinib, Erlotinib, Sunitinib, Molecular Profiling
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- High Risk for Developing Breast Cancer
- Interventions
- Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test
- Behavioral · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York